venBio

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with significant unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and a comprehensive understanding of transforming growth factor (TGF)-beta structure-function relationships to create highly effective ligand traps. These advancements aim to facilitate the development of targeted biologics for treating patients suffering from cardio-pulmonary and metabolic diseases.

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.

ViceBio is a biopharmaceutical company focused on developing innovative vaccines to combat respiratory viral infectious diseases. Utilizing its patented Molecular Clamp Technology, ViceBio stabilizes viral glycoproteins in their prefusion conformation, which allows for the creation of effective and ready-to-use liquid vaccines. This technology enables long-term storage and easy administration of vaccines targeting various respiratory viruses, including respiratory syncytial virus (RSV), metapneumovirus, influenza, and SARS-CoV-2. Through its commitment to advancing vaccination strategies, ViceBio aims to prevent potentially fatal infections caused by these viruses.

Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides, which possess antibody-like binding affinity. Utilizing an automated platform that integrates molecular biology and parallel synthetic chemistry, Insamo aims to rapidly identify preclinical candidates with favorable pharmacological properties. This innovative approach enables the potential replacement of traditional injected or infused biologics with more accessible oral formulations, thereby enhancing patient care. The company's automated design, synthesis, and testing processes allow for unprecedented scalability in the discovery of these therapeutic compounds.

Attralus, Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from systemic amyloidosis. The company develops innovative peptide-based agents aimed at diagnosing and treating various forms and stages of this complex condition. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic applications; and AT-03, an Fc-fusion protein designed for therapeutic use. Attralus focuses on addressing the common pathology found in all systemic amyloidosis diseases, striving to create effective treatments for subtypes that currently lack available options. Founded in 2010 and headquartered in South San Francisco, California, Attralus was previously known as Aurora Bio, Inc. before rebranding in August 2020.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company specializes in targeted radiotherapies that employ purpose-built vectors to deliver high-energy radioisotopes directly to tumors and metastatic lesions. This innovative approach aims to provide more effective treatment options for patients, capitalizing on the significant therapeutic and commercial potential of TATs. With the nuclear medicine market projected to grow substantially, Abdera's targeted therapies are positioned to play a crucial role in the evolving landscape of cancer treatment.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted radiotherapy (TRT) treatments for cancer patients. The company aims to introduce innovative TRT products to the Chinese market, leveraging the founders' extensive experience and networks in cross-border product development and deal-making. By focusing on advanced therapeutic solutions, Ablaze Pharmaceuticals seeks to improve the outcomes and quality of life for cancer patients in China.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

HistoWiz, Inc. is a histology service company based in Brooklyn, New York, that specializes in processing, embedding, cutting, and staining mouse tissue specimens for cancer researchers in academia and the pharmaceutical industry. Founded in 2012, HistoWiz operates a fully automated histology laboratory and has developed an innovative online pathologist network. The company digitizes tissue samples and stores them in PathologyMap, its cloud database, which serves as a valuable resource for researchers. This platform not only facilitates rapid information exchange among medical scientists and research pathologists but also enhances data management and supports the integration of technology in pathology. By automating histopathology processes, HistoWiz aims to accelerate research and contribute to the discovery of new treatments for cancer.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Attralus, Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from systemic amyloidosis. The company develops innovative peptide-based agents aimed at diagnosing and treating various forms and stages of this complex condition. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic applications; and AT-03, an Fc-fusion protein designed for therapeutic use. Attralus focuses on addressing the common pathology found in all systemic amyloidosis diseases, striving to create effective treatments for subtypes that currently lack available options. Founded in 2010 and headquartered in South San Francisco, California, Attralus was previously known as Aurora Bio, Inc. before rebranding in August 2020.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Artiva Biotherapeutics is a biotech company focused on developing and manufacturing cellular immunotherapies for cancer patients. Founded in 2019 and based in San Diego, California, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating various hematologic cancers and solid tumors. The company's product pipeline targets specific antigens, including CD20 and CD19 for B-cell lymphomas, as well as HER2 for certain solid tumors. Artiva's approach emphasizes the therapeutic potential of NK cells and aims to overcome challenges in scaling and manufacturing these therapies. The company is committed to delivering safe, effective, and readily accessible cell therapies to benefit cancer patients. Artiva operates as a subsidiary of Green Cross Holdings Corporation.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Tallac Therapeutics is a biopharmaceutical company based in Burlingame, California, focused on developing innovative immunotherapies for cancer patients. Established in 2018, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate the immune system in a targeted manner, enhancing both innate and adaptive immunity to effectively combat various solid tumor malignancies. By providing advanced treatment options, Tallac Therapeutics seeks to improve patient outcomes in the fight against cancer.

Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Stargazer Pharmaceuticals Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2018. The company specializes in developing and manufacturing therapies for rare eye diseases, with a particular focus on Stargardt’s disease, a form of juvenile retinal degeneration. Currently operating in stealth mode, Stargazer Pharmaceuticals aims to provide novel treatment options for conditions that lack existing therapies, thus enabling healthcare professionals to better address the needs of patients with these rare diseases.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Attralus, Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from systemic amyloidosis. The company develops innovative peptide-based agents aimed at diagnosing and treating various forms and stages of this complex condition. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic applications; and AT-03, an Fc-fusion protein designed for therapeutic use. Attralus focuses on addressing the common pathology found in all systemic amyloidosis diseases, striving to create effective treatments for subtypes that currently lack available options. Founded in 2010 and headquartered in South San Francisco, California, Attralus was previously known as Aurora Bio, Inc. before rebranding in August 2020.

Artiva Biotherapeutics is a biotech company focused on developing and manufacturing cellular immunotherapies for cancer patients. Founded in 2019 and based in San Diego, California, Artiva specializes in off-the-shelf, allogeneic natural killer (NK) cell therapies aimed at treating various hematologic cancers and solid tumors. The company's product pipeline targets specific antigens, including CD20 and CD19 for B-cell lymphomas, as well as HER2 for certain solid tumors. Artiva's approach emphasizes the therapeutic potential of NK cells and aims to overcome challenges in scaling and manufacturing these therapies. The company is committed to delivering safe, effective, and readily accessible cell therapies to benefit cancer patients. Artiva operates as a subsidiary of Green Cross Holdings Corporation.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Aeovian Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for age-related and rare diseases. Founded in 2012 and based in the San Francisco Bay Area, the company specializes in compounds that inhibit the mTORC1 and mTORC2 pathways. These therapeutics aim to address the underlying causes of disease initiation and progression, including oxidative, cellular, and environmental stress. By targeting these fundamental factors, Aeovian Pharmaceuticals seeks to provide effective treatment options for patients and healthcare professionals.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Impel Pharmaceuticals is a late-stage pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with significant unmet medical needs, particularly in central nervous system disorders. The company employs its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery directly to the vascular-rich upper nasal space, facilitating the administration of various therapeutic formulations. Impel's product pipeline includes TRUDHESA™, designed for the acute treatment of migraines, INP105 for managing agitation and aggression in individuals with autism, and INP107 for addressing OFF episodes in Parkinson’s disease. By focusing on these transformative therapies, Impel aims to improve patient outcomes and address critical health challenges.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative small molecule targeted therapies for oncology. The company designs a range of tyrosine kinase inhibitors (TKIs) aimed at addressing genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently under evaluation in the ongoing Phase I/II TRIDENT-1 trial, targeting patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point's pipeline includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, which is an ALK inhibitor in preclinical development. Founded in 2013 and headquartered in San Diego, California, the company aims to advance precision medicine in oncology by addressing unmet medical needs.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company focused on developing innovative therapies for gastrointestinal disorders. Established in 2017 and located in Campbell, California, the company aims to address the unmet medical needs associated with functional and motility disorders of the gastrointestinal tract. One of its key products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx's specialty therapies target the enteric nervous system, addressing issues related to gut contractions, sensation, and the brain-gut axis, ultimately striving to alleviate the burden of these disorders on patients and the healthcare system.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Harmony Biosciences is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary product, WAKIX (pitolisant), is designed to treat narcolepsy in pediatric patients and has a unique mechanism of action that enhances histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences aims to address critical therapeutic gaps in the treatment of neurological conditions, focusing on improving the quality of life for affected individuals.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

VYNE Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for dermatological conditions. Its flagship product, AMZEEQ, is a topical minocycline designed for the treatment of inflammatory lesions associated with moderate-to-severe acne vulgaris in patients aged nine and older. VYNE is advancing several other products, including FMX103, which is in Phase III clinical trials for moderate-to-severe papulopustular rosacea, and FCD105, a topical combination foam currently in Phase II trials for acne vulgaris. Additionally, the company is developing Serlopitant, an oral NK1 receptor antagonist aimed at alleviating pruritus linked to conditions such as prurigo nodularis. Founded in 2003 and headquartered in Bridgewater, New Jersey, VYNE Therapeutics was previously known as Menlo Therapeutics Inc. before its name change in September 2020.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Impel Pharmaceuticals is a late-stage pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with significant unmet medical needs, particularly in central nervous system disorders. The company employs its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery directly to the vascular-rich upper nasal space, facilitating the administration of various therapeutic formulations. Impel's product pipeline includes TRUDHESA™, designed for the acute treatment of migraines, INP105 for managing agitation and aggression in individuals with autism, and INP107 for addressing OFF episodes in Parkinson’s disease. By focusing on these transformative therapies, Impel aims to improve patient outcomes and address critical health challenges.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, founded in 2007. The company specializes in developing T cell therapies aimed at treating cancer, human immunodeficiency virus, and infectious diseases. Adaptimmune employs a proprietary platform that allows it to identify cancer targets, engineer T-cell receptors, and produce therapeutic candidates for patient administration. Its innovative approach strengthens patient T cell responses through the use of affinity T cell receptor proteins to target and eliminate cancerous or infected cells. The company’s therapeutic programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell therapy, and CD70, among others, addressing various cancer types.

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.

Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Stem Cell Therapeutics Corp. is a Toronto-based biopharmaceutical company focused on developing innovative cancer therapies derived from cancer stem cell research. As the only public entity in Canada dedicated to this field, the company leverages over 50 years of pioneering research in stem cells, collaborating with prominent academic institutions and oncology treatment centers in Toronto, a renowned hub for cancer research. In addition to its cancer initiatives, the company is also involved in creating drug-based therapies aimed at treating central nervous system diseases. These therapies stimulate a patient's own resident stem cells to facilitate the repair of neurological functions impaired by conditions such as stroke, traumatic brain injury, and multiple sclerosis, aiming to restore health in patients suffering from various neurodegenerative disorders.

Seragon Pharmaceuticals, Inc., based in Irvine, California, is a research-focused biopharmaceutical company dedicated to enhancing human and animal health through innovative scientific advancements. The company specializes in the development of orally active selective estrogen receptor degraders (SERDs), particularly targeting metastatic breast cancer. Its lead drug candidate, ARN-810, is currently under evaluation for the treatment of estrogen receptor-positive breast cancer. By leveraging cutting-edge research in metabolism, gene therapy, and bioinformatics, Seragon Pharmaceuticals aims to facilitate access to significant medical breakthroughs, encompassing both clinical applications and consumer products.

Solstice Biologics LLC is a biotechnology company focused on developing small, cell-permeable RNA interference (RNAi) pro-drugs aimed at enhancing the targeting and delivery of nucleic acid therapeutics. Founded in 2012 and based in San Diego, California, the company specializes in creating innovative solutions that allow for the effective entry of therapeutic agents into various cell types. By utilizing small double-stranded cellular RNA to selectively degrade specific messenger RNAs, Solstice Biologics addresses critical challenges in the field of RNAi therapeutics, facilitating the advancement of new treatments.

Labrys Biologics Inc. is a biotechnology company dedicated to developing treatments for chronic migraine. The company has secured worldwide rights to RN-307, an antibody initially developed by Pfizer Inc., specifically designed for the treatment of chronic migraine. Additionally, Labrys Biologics is advancing its lead candidate, LBR-101, which is an anti-CGRP monoclonal antibody aimed at preventing chronic and high-frequency migraines. Through these innovative therapies, Labrys Biologics aims to address the significant unmet medical needs of individuals suffering from chronic migraine conditions.

Solstice Biologics LLC is a biotechnology company focused on developing small, cell-permeable RNA interference (RNAi) pro-drugs aimed at enhancing the targeting and delivery of nucleic acid therapeutics. Founded in 2012 and based in San Diego, California, the company specializes in creating innovative solutions that allow for the effective entry of therapeutic agents into various cell types. By utilizing small double-stranded cellular RNA to selectively degrade specific messenger RNAs, Solstice Biologics addresses critical challenges in the field of RNAi therapeutics, facilitating the advancement of new treatments.

Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.